Guerbet SA (EPA:GBT)

Market Cap	172.89M -49.3%
Revenue (ttm)	820.92M -2.4%
Net Income	7.74M -76.4%
EPS	0.61 -76.3%
Shares Out	12.60M
PE Ratio	22.34
Forward PE	571.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,257
Average Volume	8,903
Open	13.66
Previous Close	13.66
Day's Range	13.58 - 13.72
52-Week Range	11.18 - 28.20
Beta	0.76
RSI	38.24
Earnings Date	Mar 11, 2026

About Guerbet

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine; Elucirem, a macrocyclic gadolinium-based contrast agent; and Artirem, a gadoteric acid that acts a...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1926
• Employees: 2,905
• Stock Exchange: Euronext Paris
• Ticker Symbol: GBT

Financial Performance

In 2024, Guerbet's revenue was 851.12 million, an increase of 6.97% compared to the previous year's 795.65 million. Earnings were 16.08 million, a decrease of -32.61%.